Prognostic utility of serum vitronectin levels in acute myocardial infarction

详细信息    查看全文

• 作者：S. Aslan ; B. Ikitimur ; H.A. Cakmak ; B. Karadag ; E.Y. Tufekcioglu ; H. Ekmekci…
• 关键词：Vitronectin ; Prognosis ; Acute myocardial infarction ; ST ; elevation myocardial infarction ; Major adverse cardiovascular events ; Vitronectin ; Prognose ; Akuter Myokardinfarkt ; ST ; Strecken ; Hebungs ; Infarkt ; Gr??ere unerwünschte kardiovaskul?re Ereignisse
• 刊名：Herz
• 出版年：2015
• 出版时间：June 2015
• 年：2015
• 卷：40
• 期：4
• 页码：685-689
• 全文大小：390 KB
• 参考文献：1.Schvartz I, Seger D, Shaltiel S (1999) Vitronectin. Int J Biochem Cell Biol 31:539-44PubMed View Article
  2.Preissner KT, Seiffert D (1998) Role of vitronectin and its receptors in hemostasis and vascular remodeling. Thromb Res 89:1-1PubMed View Article
  3.Fay WP, Parker AC, Ansari MN et al (1999) Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 93:1825-830PubMed
  4.Zhuang P, Blackburn MN, Peterson CB (1996) Characterization of the denaturation and renaturation of human plasma vitronectin: I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem 271:14323-4332PubMed View Article
  5.Preissner KT, Reuning U (2011) Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37:408-24PubMed View Article
  6.Seiffert D (1997) Constitutive and regulated expression of vitronectin. Histol Histopathol 12:787-97PubMed
  7.Seiffert D, Geisterfer M, Gauldie J et al (1995) IL-6 stimulates vitronectin gene expression in vivo. J Immunol 155(6):3180-185PubMed
  8.Van Aken BE, Seiffert D, Thinnes T, Loskutoff DJ (1997) Localization of vitronectin in the normal and atherosclerotic human vessel wall. Histochem Cell Biol 107(4):313-20View Article
  9.Niculescu F, Rus HG, Vlaicu R (1987) Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65(1-):1-1
  10.Guettier C, Hinglais N, Bruneval P et al (1989) Immunohistochemical localization of S protein/vitronectin in human atherosclerotic versus arteriosclerotic arteries. Virchows Arch A Pathol Anat Histopathol 414:309-13PubMed View Article
  11.Dufourcq P, Louis H, Moreau C et al (1998) Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscler Thromb Vasc Biol 18:168-76PubMed View Article
  12.Ekmekci H, Sonmez H, Ekmekci OB et al (2002) Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis 14:221-25PubMed View Article
  13.Derer W, Barnathan ES, Safak E et al (2009) Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv 2:14-9PubMed View Article
  14.Thygesen K, Alpert JS, Jaffe AS et al (2012) Third universal definition of myocardial infarction. Eur Heart J 33:2551-567PubMed View Article
  15.Ekmekci OB, Ekmekci H (2006) Vitronectin in atherosclerotic disease. Clin Chim Acta 368:77-3PubMed View Article
  16.Thiagarajan P, Kelly KL (1988) Exposure of binding sites of vitronectin on platelets following stimulation. J Biol Chem 263:3035-038PubMed
  17.Asch E, Podack E (1990) Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest 85:1372-378PubMed Central PubMed View Article
  18.Mohri H, Ohkubo T (1991) How vitronectin binds to activated glycoprotein IIb/IIIa complex and its function in platelet aggregation. Am J Clin Pathol 96:605-09PubMed
  19.Sinning C, Lillpopp L, Appelbaum S et al (2013) Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol 102:495-03PubMed View Article
  20.Newall F, Johnston L, Ignjatovic V et al (2009) Age-related plasma reference ranges for two heparin-binding proteins-vitronectin and platelet factor 4. Int J Lab Hematol 6:683-87View Article
  
• 作者单位：S. Aslan (1)
  B. Ikitimur (1)
  H.A. Cakmak (1)
  B. Karadag (1)
  E.Y. Tufekcioglu (2)
  H. Ekmekci (3)
  H. Yuksel (1)
  
  1. Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul University, Istanbul, Turkey
  2. Cerrahpasa Medical Faculty, Department of Public Health, Istanbul University, Istanbul, Turkey
  3. Cerrahpasa Medical Faculty, Department of Biochemistry, Istanbul University, Istanbul, Turkey
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  
• 出版者：Urban & Vogel
• ISSN：1615-6692

文摘

Background Vitronectin (VN) functions as a regulator of platelet adhesion and aggregation, coagulation, and fibrinolysis. The aim of this study was to assess the prognostic significance of serum VN levels in patients with acute myocardial infarction (MI). Methods In this study 62 patients admitted with ST-elevation myocardial infarction (STEMI), or non-ST-elevation myocardial infarction (NSTEMI) were enrolled. Serum VN levels were measured within 6?h after onset of chest pains. Results The VN serum levels were higher in MI patients with a mean of 2.257?μg/ml (range 1.541-.493?μg/ml) in the STEMI group, 1.785?μg/ml (range 1.372-.113?μg/ml) in the NSTEMI group, and 1.222?μg/ml (range 1.033-.466?μg/ml) in the controls (p--.012). Major adverse cardiovascular events could be predicted at 6 months using VN levels independently of other variables [odds ratio (OR) 9.87, 95- confidence interval (CI) 2.54-7.37, p--.001]. There was a significant positive correlation between VN levels and the Gensini score in NSTEMI patients (r--.436, p--.013). Conclusion The VN level may be relevant as a clinical biomarker for adverse cardiovascular outcomes not only in patients with ischemic heart disease undergoing coronary interventions, as previously reported, but also in coronary artery disease patients presenting with acute MI.